BioSpace News Archive

Algernon Pharmaceuticals Inc. reports that the Company has granted 96,000 stock options exercisable at $4.10 for five years from date of grant, for officers and directors, employees and a consultant and are subject to approval by regulatory authorities.

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today announced that presentation of the company’s Phase IIa clinical trial results have been accepted at the 16th International Conference on Alzheimer’s & Parkinson’s (AD/PD) to be held in Barcelona in March 2022.

Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that its management team will present at the H.C. Wainwright BIOCONNECT Virtual Conference being held January 10-13, 2022.

Exelixis, Inc. announced the appointment of Vicki L. Goodman, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer.

Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first‑in‑class medicines for sedation and analgesia, today announced the filing of two investigational new drug applications (INDs) with the U.S. Food and Drug Administration (FDA) for two sublingual, IV-free, non‑opioid formulations – MELT-210 (midazolam) for procedural sedation and MELT-400 (ketamine) for pain.

Amylyx Pharmaceuticals, Inc. today announced it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for AMX0035 (sodium phenylbutyrate (PB) and ursodoxicoltaurine (TURSO; also known as taurursodiol)) for the treatment of amyotrophic lateral sclerosis (ALS).

BioLife Solutions, Inc. (NASDAQ: BLFS), today announced an extended collaboration with Seattle Children’s Therapeutics, a venture at Seattle Children’s, bringing cutting edge, curative technologies and therapies to defeat pediatric cancer and other diseases that impact children.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, today announced completion of enrollment in Part 1 of the Phase 3 GUARD Trial of ADX-2191 (intravitreal methotrexate 0.8%) in patients with proliferative vitreoretinopathy (PVR).

AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference.

Equillium, Inc. (Nasdaq: EQ), today announced publication of a manuscript featured on the front cover of the Journal of Clinical Investigation (www.jci.org/this-month), confirming the role of T cells activated by the CD6-ALCAM pathway in the development of lupus nephritis (LN).